Previously volume-limited licenses for generic versions of Revlimid will become unlimited after January 31, 2026. This will expose a major product to full generic competition, leading to accelerated revenue decline and intense pricing pressure in the US market.
Filing excerpt
For Revlimid, in the U.S., certain generic companies have begun marketing generic lenalidomide products pursuant to volume-limited licenses granted as part of litigation settlements.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kmarketShareLossGet every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/8c9fe6ba-611c-4a98-a888-512ae94e9f51 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "8c9fe6ba-611c-4a98-a888-512ae94e9f51",
"signal_type": "sec-10k",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-02-17T06:30:02.078+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "Previously volume-limited licenses for generic versions of Revlimid will become unlimited after January 31, 2026. This will expose a major product to full generic competition, leading to accelerated revenue decline and intense pricing pressure in the US market.",
"metrics": {
"timeframe": "next_year"
},
"summary": "Revlimid faces unlimited generic competition in the US starting January 31, 2026",
"excerpts": "For Revlimid, in the U.S., certain generic companies have begun marketing generic lenalidomide products pursuant to volume-limited licenses granted as part of litigation settlements.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Urgency to improve",
"signal_category": "market",
"regions_mentioned": [
"U.S.",
"EU",
"Japan"
]
}
}
curl https://signals.autobound.ai/v1/signals/8c9fe6ba-611c-4a98-a888-512ae94e9f51 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.